Navigation Links
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
Date:6/15/2010

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., June 15, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON™ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

This 26-week clinical study compared BYDUREON monotherapy to Januvia® (sitagliptin), Actos® (pioglitazone HCI) or metformin, three oral type 2 diabetes medications commonly prescribed early in the treatment of type 2 diabetes. Study participants were not achieving adequate A1C control using diet and exercise, and were not on any diabetes therapy when they entered the study. A1C is a measure of average blood sugar over three months. After 26 weeks of treatment, patients randomized to BYDUREON experienced a reduction in A1C of 1.5 percentage points from baseline, which was significantly greater than the reduction of 1.2 percentage points for Januvia. Patients randomized to metformin experienced a reduction in A1C of 1.5 percentage points, and patients receiving Actos experienced a reduction of 1.6 percentage points. Patients receiving BYDUREON, Actos and metformin treatment achieved an average A1C of less than 7 percent by study end.

Treatment with B
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... Holdings, Inc. (OTC Bulletin Board: ADLS ), announced ... discussing the Company,s 2010 fourth quarter and full-year financial results ... T. Flavin, Ph.D., Chairman & Chief Executive Officer, as well ... an update on the Company. A press release reporting the ...
... March 17, 2011 Delta Point, Inc., a consulting ... business relationships, has named Ed Weimer as Executive Account ... for his ability to highly motivate, develop and inspire ... strategic vision to contribute to the organization,s goals. ...
... SHANGHAI, March 17, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... leading developer, manufacturer and distributor of probiotics products in ... categories of strain formula supplied to Bright Dairy. ... formulas that it supplies to Bright Dairy, one of ...
Cached Biology Technology:Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2China-Biotics Expands Product Supplied to Bright Dairy 2China-Biotics Expands Product Supplied to Bright Dairy 3
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... American College of Sports Medicine,s Conference on Integrative ... Miami, Florida. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the American College ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability ... disability that occurs when the regions of the ... , The use of non-invasive functional neuroimaging tools ... in dyslexia. However, most prior work has focused ... leaving a gap in our understanding of how ...
(Date:8/28/2014)... could pose a significant health risk to people with asthma ... of Allergy and Clinical Immunology . , By critically reviewing ... research has found that the presence of several types of ... well as increasing the likelihood of developing the condition. , ... University of Exeter Medical School and is the first time ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2
... A well-preserved fossil discovered in northeast China provides new ... species--the placental mammals. According to a paper published today ... new milestone in mammal evolution that was reached 35 million ... gap in the fossil record and helps to calibrate modern, ...
... This press release is available in French . ... the severity of brain damage after a stroke, according to a ... Jasna Kriz and Frdric Calon, showed that the extent of brain ... consumed DHA type omega-3s daily. Details of the study can be ...
... new method of single molecule DNA sequencing is being ... funding from the Biotechnology and Biological Sciences Research Council,s ... The aim of the research is to create novel ... strands. The human genome contains 3164.7 million nucleic ...
Cached Biology News:Fossil discovery represents new milestone in early mammal evolution 2Fossil discovery represents new milestone in early mammal evolution 3Omega-3s reduce stroke severity 2
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
... gun system, 220-240 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
Biology Products: